Royalty Pharma plc financial data

Symbol
RPRX on Nasdaq
Location
110 East 59 Th Street, New York, NY
Fiscal year end
December 31
Latest financial report
10-Q - Q2 2025 - Aug 6, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 145 % -86%
Return On Equity 10.2 % +49.3%
Return On Assets 5.66 % +38.7%
Operating Margin 79.8 % +86.1%

Shares

Label TTM Value / Value Unit Change %
Entity Public Float 13.1B USD -4.38%
Weighted Average Number of Shares Outstanding, Basic 424M shares -6.1%
Weighted Average Number of Shares Outstanding, Diluted 562M shares -5.8%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 2.31B USD +3.02%
Research and Development Expense 352M USD +577%
General and Administrative Expense 415M USD +81.3%
Costs and Expenses 465M USD -63.6%
Operating Income (Loss) 1.84B USD +91.7%
Nonoperating Income (Expense) -176M USD -353%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest 1.66B USD +61.7%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent 1.02B USD +51.6%
Earnings Per Share, Basic 2 USD/shares +52.3%
Earnings Per Share, Diluted 2 USD/shares +51.7%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 632M USD -64.2%
Other Assets, Current 4.45M USD +94.2%
Assets, Current 1.52B USD -41.1%
Goodwill 925M USD
Other Assets, Noncurrent 85.5M USD +210%
Assets 18.3B USD +3.77%
Liabilities, Current 1.21B USD +338%
Other Liabilities, Noncurrent 143M USD +430%
Liabilities 8.82B USD +11.6%
Retained Earnings (Accumulated Deficit) 2.22B USD -6.54%
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest 9.5B USD -2.55%
Liabilities and Equity 18.3B USD +3.77%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities 596M USD -10.3%
Net Cash Provided by (Used in) Financing Activities -941M USD -344%
Net Cash Provided by (Used in) Investing Activities 504M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 159M USD -56.6%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 632M USD -64.2%
Interest Paid, Excluding Capitalized Interest, Operating Activities 139M USD +75.8%
Operating Lease, Liability 20.8M USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent 1.13B USD +4401%
Lessee, Operating Lease, Liability, to be Paid 24.2M USD
Lessee, Operating Lease, Liability, to be Paid, Year Two 3.78M USD
Lessee, Operating Lease, Liability, to be Paid, Year One 4.05M USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 3.41M USD
Lessee, Operating Lease, Liability, to be Paid, Year Three 3.72M USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 3.73M USD
Additional Paid in Capital 4.13B USD +0.66%
Amortization of Intangible Assets 0 USD -100%
Share-based Payment Arrangement, Expense 91M USD
Interest Expense 184M USD -1.8%